Valeant to name four new directors as soon as Friday: WSJ

(Reuters) - Drugmaker Valeant Pharmaceuticals International Inc is expected to name four new directors as soon as Friday, the Wall Street Journal reported. Five of its long-standing directors, including activist firm ValueAct's Mason Morfit, have agreed to step down to make room for the new nominees, the Journal reported, citing people familiar with the matter. Valeant chairman Robert Ingram is also considering leaving, the report said, citing a source.